Replimune (REPL) Depreciation & Amortization (CF) (2017 - 2026)
Replimune (REPL) posted Depreciation & Amortization (CF) of $700000.0 for Q1 2026, down 12.5% sequentially from $800000.0 in Q4 2025, and down 17.26% YoY from $846000.0 in Q1 2025.
Powered by 
Analysis
Replimune (REPL) Depreciation & Amortization (CF) (2017 - 2026) Analysis & Trends
Replimune has reported Depreciation & Amortization (CF) for 10 years, with the latest figure at $700000.0 in Q1 2026.
- Quarterly Depreciation & Amortization (CF) fell 17.26% year-over-year to $700000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.2 million (down 8.1% YoY) and the FY2026 annual result came in at $3.3 million, down 5.71% from the prior year.
- Depreciation & Amortization (CF) retreated to $700000.0 in Q1 2026 per REPL's latest filing, from $800000.0 in the prior quarter.
- Over five years, Depreciation & Amortization (CF) peaked at $1.0 million in Q4 2024 and troughed at $481000.0 in Q1 2023.
- A 5-year average of $724117.6 and a median of $700000.0 in 2023 frame the typical range for Depreciation & Amortization (CF).
- The sharpest annual moves came in 2024 and 2025: Depreciation & Amortization (CF) soared 46.57% in 2024, then dropped 20.0% in 2025.
- Over 5 years, Depreciation & Amortization (CF) stood at $682000.0 in 2022, then climbed by 2.64% to $700000.0 in 2023, then jumped by 42.86% to $1.0 million in 2024, then slipped by 20.0% to $800000.0 in 2025, then retreated by 12.5% to $700000.0 in 2026.
- According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $700000.0, $800000.0, and $800000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 40.52 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Replimune | 1.46 Bn | 1.46 Bn | - | 937,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 937,000.00 |
| Mar 31, 2026 | 732,000.00 |
| Dec 31, 2025 | 800,000.00 |
| Sep 30, 2025 | 800,000.00 |
| Jun 30, 2025 | 900,000.00 |
| Mar 31, 2025 | 802,000.00 |
| Dec 31, 2024 | 1.00 Mn |
| Sep 30, 2024 | 900,000.00 |
| Jun 30, 2024 | 736,000.00 |
| Mar 31, 2024 | 700,000.00 |
| Dec 31, 2023 | 700,000.00 |
| Sep 30, 2023 | 700,000.00 |
| Jun 30, 2023 | 621,000.00 |
| Mar 31, 2023 | 528,000.00 |
| Dec 31, 2022 | 682,000.00 |
| Sep 30, 2022 | 617,000.00 |
| Jun 30, 2022 | 620,000.00 |
| Mar 31, 2022 | 549,000.00 |
| Dec 31, 2021 | 548,000.00 |
| Sep 30, 2021 | 532,000.00 |